Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Gemcitabine: a new chemotherapy agent for solid cancers]

J Klastersky1, A Awada

  • 1Service de Médecine Interne, Institut Jules Bordet, l'Université Libre de Bruxelles.

Revue Medicale De Bruxelles
|January 24, 1998
PubMed
Summary

Gemcitabine, a novel chemotherapy, shows promise for various cancers like pancreatic and lung. Its low toxicity and effectiveness in combination therapies make it valuable for palliative care and radiotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Final results from the phase Ia/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphoma.

ESMO open·2025
Same author

How I treat endocrine-dependent metastatic breast cancer.

ESMO open·2023
Same author

Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancer: a survey of oncologist perceptions.

ESMO open·2023
Same author

Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment.

ESMO open·2022
Same author

Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis.

ESMO open·2022

Area of Science:

  • Oncology
  • Pharmacology

Context:

  • Gemcitabine is a new nucleotide analogue with significant therapeutic potential.
  • It is indicated for pancreatic, lung, ovarian, and breast carcinomas.

Purpose:

  • To evaluate gemcitabine as a chemotherapeutic agent.
  • To assess its efficacy in combination with other anticancer agents and radiotherapy.

Summary:

  • Gemcitabine exhibits low toxicity, primarily hematologic, making it suitable for palliative care.
  • Combinations with cisplatin and anthracyclines show high response rates.
  • Gemcitabine acts as a potent radiosensitizing agent, beneficial in locally advanced diseases.

Impact:

  • Gemcitabine offers a viable treatment option for patients intolerant to aggressive therapies.

Related Experiment Videos

  • Its combination potential enhances treatment efficacy and response rates.
  • Gemcitabine is a key candidate for combined radiotherapy protocols.